2403-66-9Relevant articles and documents
Selective nitrogen protection of hydroxyalkylbenzimidazoles using 2,2,2-trichloroethylchloroformate
Woudenberg, Richard C.,Coughlin, E. Bryan
, p. 6311 - 6313 (2005)
A method for selective N-protection of hydroxyalkylbenzimidazoles using 2,2,2-trichloroethylchloroformate (Troc-Cl) applicable to various alkyl chain lengths has been developed. In the specific case of 5-(1-[2,2,2-trichloroethyl formyl]-benzimidazol-2-yl)-propan-1-ol, migration of Troc from the benzimidazole to the primary alcohol occurs in the presence of triethylamine, allowing the choice of selective N-Troc or O-Troc protection.
Synthesis, anti-proliferative activity, SAR study, and preliminary in vivo toxicity study of substituted N,N′-bis(arylmethyl)benzimidazolium salts against a panel of non-small cell lung cancer cell lines
Shelton, Kerri L.,DeBord, Michael A.,Wagers, Patrick O.,Southerland, Marie R.,Williams, Travis M.,Robishaw, Nikki K.,Shriver, Leah P.,Tessier, Claire A.,Panzner, Matthew J.,Youngs, Wiley J.
, p. 421 - 439 (2016/12/18)
A series of N,N′-bis(arylmethyl)benzimidazolium salts have been synthesized and evaluated for their in vitro anti-cancer activity against select non-small cell lung cancer cell lines to create a structure activity relationship profile. The results indicate that hydrophobic substituents on the salts increase the overall anti-proliferative activity. Our data confirms that naphthylmethyl substituents at the nitrogen atoms (N1(N3)) and highly lipophilic substituents at the carbon atoms (C2and C5(C6)) can generate benzimidazolium salts with anti-proliferative activity that is comparable to that of cisplatin. The National Cancer Institute's Developmental Therapeutics Program tested 1, 3–5, 10, 11, 13–18, 20–25, and 28–30 in their 60 human tumor cell line screen. Results were supportive of data observed in our lab. Compounds with hydrophobic substituents have higher anti-cancer activity than compounds with hydrophilic substituents.
Trimethylsilyl chloride catalyzed synthesis of substituted benzimidazoles using two phase system under microwave conditions, and their antimicrobial studies
Karuvalam, Ranjith P.,Haridas, Karickal R.,Shetty, Suchetha N.
, p. 1122 - 1125,4 (2020/08/24)
A convenient method using TMSCl (20 mol%) and microwave-induced technique for the synthesis of various benzimidazole is described. This has reduced the reaction time drastically as well as improved the yield when compared to conventional heating. The synthesized compounds were evaluated for their in vitro antibacterial and antifungal activities against four strains each. Preliminary results indicated that, compounds 3e, 3f, 3g, 3k, 3m, 3n and 3o demonstrated very good antimicrobial activity, comparable to the first line standard drugs. The most effective compounds have exhibited activity at MIC of 6.25 μg/mL.
Boric acid-catalyzed direct condensation of carboxylic acids with benzene-1,2-diamine into benzimidazoles
Maras, Nenad,Kocevar, Marijan
experimental part, p. 1860 - 1874 (2011/12/02)
The applicability of boric acid catalysis for the direct condensation of carboxylic acids with benzene-1,2-diamine to give 2-substituted benzimidazoles was investigated. It was found that catalytic amounts (5-10 mol-%) of boric acid efficiently promote the cyclocondensation of aliphatic carboxylic acids in refluxing toluene. In addition, the relatively neutral conditions allow the use of acid-sensitive substrates and give rise to specific transformations and selectivities that are not observed with some classical methods. Benzoic acids were found to be less reactive than aliphatic acids and thus require refluxing xylene for better efficiency. Phenylboronic acid was found to be inactive as a catalyst due to its rapid consumption by condensation with benzene-1,2-diamine to give a 2-phenylbenzodiazaborole. Copyright
Tetra butyl ammonium chloride catalyzed synthesis of substituted benzimidazoles under microwave conditions
Ranjith, P. Karuvalam,Siji,Divia,Karickal, R. Haridas
experimental part, p. 589 - 593 (2011/01/12)
TBACl (10 mol %) was found to be a useful catalyst for the synthesis of substituted benzimidazoles. The method was proved to be simple, convenient and the product was isolated with good yield.
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication
Skerlj, Renato T.,Bridger, Gary J.,Kaller, Al,McEachern, Ernest J.,Crawford, Jason B.,Zhou, Yuanxi,Atsma, Bem,Langille, Jonathon,Nan, Susan,Veale, Duane,Wilson, Trevor,Harwig, Curtis,Hatse, Sigrid,Princen, Katrien,De Clercq, Erik,Schols, Dominique
supporting information; experimental part, p. 3376 - 3388 (2010/09/05)
The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure-activity relationship (SAR) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N′-((1H-benzo[d]imidazol-2-yl)methyl)- N′-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 μM. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.
Nitrogen versus oxygen group protection in hydroxypropylbenzimidazoles
Indusegaram, Sutharsiny,Katsifis, Andrew G.,Ridley, Damon D.,Vonwiller, Simone C.
, p. 819 - 827 (2007/10/03)
In order to convert 1′ H-benzimidazol-2′-ylpropanols into aryl ethers using Mitsunobu coupling, it was necessary to protect the benzimidazole nitrogen in the starting alcohols. Selective protection at nitrogen was achieved through N-benzyl derivatives, but attempts to protect the nitrogen directly through tert-butoxycarbonyl, acetyl, trityl, or tetrahydropyranyl derivatives were complicated either by selective reactions at oxygen or by the formation of bis-protected compounds. Transformations of some oxygen-protected derivatives are discussed, and in particular the conversion of the acetates of 1′H-benzimidazol-2′-ylpropanols to N-tetrahydropyranyl derivatives is described. Mitsunobu coupling involving the N-benzyl and N-tetrahydropyranyl derivatives and methyl 4-hydroxybenzoate were achieved, and thus afforded synthetic routes to the desired propylbenzimidazole aryl ethers.
8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
-
, (2008/06/13)
Novel 3-substituted 8-aza-bicyclo[3.2.1]octanes (commonly known as “tropanes”) substituted in the 8-position are effective as NMDA NR2B antagonists useful for relieving pain.
1,4 substituted piperidinyl NMDA/NR2B antagonists
-
, (2008/06/13)
Novel piperidinyl compounds substituted in the 1- and 4-positions are effective as NMDA NR2B antagonists useful for relieving pain.
